| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | PRER14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | Anika Therapeutics, Inc. |
| Entity Central Index Key | 0000898437 |
| Pay vs Performance Disclosure Unit_pure in Millions | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||
| Jan. 31, 2020 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
| Pay vs Performance Disclosure [Table] | |||||
| Pay vs Performance [Table Text Block] | Pay Versus Performance Disclosur e As required by the Dodd-Frank Act and Item 402(v) of Regulation S-K, the Pay versus Performance Value of initial fixed $100 Year Summary Summary Compensation Compensation Average non-PEO NEOs Average non-PEO Total Peer Total Return Net Revenue (a) (b) (a) (b) (c) (c) (d) (d) (e) (e) 2022 $ 5,940,722 N/A $ 3,599,763 N/A $ 1,739,011 $ 1,406,419 $ 57 $ 111 ($ 15 ) $ 156 2021 $ 4,202,608 N/A $ 1,818,313 N/A $ 1,234,846 $ 1,051,797 $ 69 $ 125 $ 4 $ 148 2020 $ 10,029,434 $ 288,753 $ 10,513,388 ($ 7,088,313 ) $ 1,411,154 $ 772,039 $ 87 $ 126 ($ 24 ) $ 130 (a) Dr. Blanchard served as interim CEO for part of 2020 and was appointed President and CEO in April 2020. (b) Mr. Darling , CEO at the beginning of 2020, passed away unexpectedly in January 2020. All of Mr. Darling’s unvested equity was forfeited upon his death. (c) NEOs in 2022 include Messrs. Levitz and Colleran, NEOs in 2021 include Messrs. Levitz, Colleran, Thomas Finnerty and James Loerop. Mr. Loerop, the company’s EVP, Business Development and Strategic Planning, resigned in January 2022. Mr. Finnerty, the company’s EVP, Human Resources, retired in March 2022. NEOs in 2020 include Messrs. Levitz, Colleran, Finnerty, Loerop and Sylvia Cheung. Ms. Cheung, the company’s CFO, resigned in August 2020. Mr. Colleran joined the company as EVP, General Counsel and Secretary in March 2020, and Mr. Levitz joined company as EVP, CFO and Treasurer in August 2020. (d) Shareholder return is based on $100 investment at the beginning of 2020. Peer shareholder return is based on the NASDAQ Biotechnology Index. (e) Net Income and Revenue are as reported in the company’s Annual Report on Form 10-K for each fiscal year referenced. | ||||
| Company Selected Measure Name | Revenue | ||||
| Named Executive Officers, Footnote [Text Block] | (c) NEOs in 2022 include Messrs. Levitz and Colleran, NEOs in 2021 include Messrs. Levitz, Colleran, Thomas Finnerty and James Loerop. Mr. Loerop, the company’s EVP, Business Development and Strategic Planning, resigned in January 2022. Mr. Finnerty, the company’s EVP, Human Resources, retired in March 2022. NEOs in 2020 include Messrs. Levitz, Colleran, Finnerty, Loerop and Sylvia Cheung. Ms. Cheung, the company’s CFO, resigned in August 2020. Mr. Colleran joined the company as EVP, General Counsel and Secretary in March 2020, and Mr. Levitz joined company as EVP, CFO and Treasurer in August 2020. | ||||
| Peer Group Issuers, Footnote [Text Block] | Shareholder return is based on $100 investment at the beginning of 2020. Peer shareholder return is based on the NASDAQ Biotechnology Index. | ||||
| Adjustment To PEO Compensation, Footnote [Text Block] | The following table sets forth a reconciliation from the summary compensation table ( SCT non-PEO PEO (Blanchard) PEO (Darling) Average NEO 2022 2021 2020 2020 2022 2021 2020 SCT Total Compensation $ 5,940,722 $ 4,202,608 $ 10,029,434 $ 288,753 $ 1,739,011 $ 1,234,846 $ 1,411,154 SUBTRACT Grant Fair Value of Equity Awards Made During Year (a) ($ 4,630,341 ) ($ 2,942,637 ) ($ 8,994,889 ) $ 0 ($ 1,051,440 ) ($ 658,333 ) ($ 962,952 ) ADD Year End Fair Value of Equity Awards Made During Year (b) $ 5,294,178 $ 3,254,974 $ 9,337,528 $ 0 $ 1,205,238 $ 728,209 $ 668,806 ADD Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards (c) ($ 1,016,462 ) ($ 2,470,476 ) $ 0 $ 0 ($ 274,828 ) ($ 189,171 ) ($ 64,142 ) ADD Year over Year Change in Fair Value of Equity Awards Granted in Prior Year that Vested in the Year (d) ($ 1,988,334 ) ($ 226,155 ) $ 0 ($ 18,351 ) ($ 211,562 ) ($ 63,754 ) ($ 83,186 ) PEO (Blanchard) PEO (Darling) Average NEO 2022 2021 2020 2020 2022 2021 2020 ADD Fair Value at Vesting of Equity Awards Made During Year $ 0 $ 0 $ 141,315 $ 0 $ 0 $ 0 $ 0 SUBTRACT Fair Value at the End of the Prior Year of Equity $ 0 $ 0 $ 0 ($ 7,358,716 ) $ 0 $ 0 ($ 197,641 ) Total Adjustments Related to Equity Awards ($ 2,340,959 ) ($ 2,384,295 ) $ 483,954 ($ 7,377,066 ) ($ 332,592 ) ($ 183,048 ) ($ 639,115 ) Compensation Actually Paid Total $ 3,599,763 $ 1,818,313 $ 10,513,388 ($ 7,088,313 ) $ 1,406,419 $ 1,051,797 $ 772,039 (a) Represents the grant date fair value of equity-based awards made during the fiscal year. (b) Represents the year-end (c) Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. (d) Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. (e) Represents the fair value on the vesting date of equity-based awards that vested in the same year as granted. In 2020, Dr. Blanchard received a grant of RSUs for her service as interim Chief Executive Officer between February and April 2020, which RSUs fully vested upon her permanent appointment as President and CEO in April 2020. (f) Represents the prior year-end fair value of equity awards that were forfeited by other PEOs who terminated during the year. Mr. Darling passed away unexpectedly in early 2020, and unvested equity awards were forfeited upon his death.. Ms. Cheung resigned in August 2020 and all unvested equity awards were forfeited upon her resignation. | ||||
| Non-PEO NEO Average Total Compensation Amount | $ 1,739,011 | $ 1,234,846 | $ 1,411,154 | ||
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 1,406,419 | 1,051,797 | 772,039 | ||
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | The following table sets forth a reconciliation from the summary compensation table ( SCT non-PEO PEO (Blanchard) PEO (Darling) Average NEO 2022 2021 2020 2020 2022 2021 2020 SCT Total Compensation $ 5,940,722 $ 4,202,608 $ 10,029,434 $ 288,753 $ 1,739,011 $ 1,234,846 $ 1,411,154 SUBTRACT Grant Fair Value of Equity Awards Made During Year (a) ($ 4,630,341 ) ($ 2,942,637 ) ($ 8,994,889 ) $ 0 ($ 1,051,440 ) ($ 658,333 ) ($ 962,952 ) ADD Year End Fair Value of Equity Awards Made During Year (b) $ 5,294,178 $ 3,254,974 $ 9,337,528 $ 0 $ 1,205,238 $ 728,209 $ 668,806 ADD Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards (c) ($ 1,016,462 ) ($ 2,470,476 ) $ 0 $ 0 ($ 274,828 ) ($ 189,171 ) ($ 64,142 ) ADD Year over Year Change in Fair Value of Equity Awards Granted in Prior Year that Vested in the Year (d) ($ 1,988,334 ) ($ 226,155 ) $ 0 ($ 18,351 ) ($ 211,562 ) ($ 63,754 ) ($ 83,186 ) PEO (Blanchard) PEO (Darling) Average NEO 2022 2021 2020 2020 2022 2021 2020 ADD Fair Value at Vesting of Equity Awards Made During Year $ 0 $ 0 $ 141,315 $ 0 $ 0 $ 0 $ 0 SUBTRACT Fair Value at the End of the Prior Year of Equity $ 0 $ 0 $ 0 ($ 7,358,716 ) $ 0 $ 0 ($ 197,641 ) Total Adjustments Related to Equity Awards ($ 2,340,959 ) ($ 2,384,295 ) $ 483,954 ($ 7,377,066 ) ($ 332,592 ) ($ 183,048 ) ($ 639,115 ) Compensation Actually Paid Total $ 3,599,763 $ 1,818,313 $ 10,513,388 ($ 7,088,313 ) $ 1,406,419 $ 1,051,797 $ 772,039 (a) Represents the grant date fair value of equity-based awards made during the fiscal year. (b) Represents the year-end (c) Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end. (d) Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year. (e) Represents the fair value on the vesting date of equity-based awards that vested in the same year as granted. In 2020, Dr. Blanchard received a grant of RSUs for her service as interim Chief Executive Officer between February and April 2020, which RSUs fully vested upon her permanent appointment as President and CEO in April 2020. (f) Represents the prior year-end fair value of equity awards that were forfeited by other PEOs who terminated during the year. Mr. Darling passed away unexpectedly in early 2020, and unvested equity awards were forfeited upon his death.. Ms. Cheung resigned in August 2020 and all unvested equity awards were forfeited upon her resignation. | ||||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | |||||
| Compensation Actually Paid vs. Net Income [Text Block] | |||||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||||
| Total Shareholder Return Vs Peer Group [Text Block] | |||||
| Tabular List [Table Text Block] | The following table sets forth what we consider to be the most important financial performance measures in how CAP was linked to company performance during 2022. Key Financial Measures Revenues Gross Margin Adjusted EBITDA | ||||
| Total Shareholder Return Amount | $ 57 | 69 | 87 | ||
| Peer Group Total Shareholder Return Amount | 111 | 125 | 126 | ||
| Net Income (Loss) | $ (15,000,000) | $ 4,000,000 | $ (24,000,000) | ||
| Company Selected Measure Amount | 156 | 148 | 130 | ||
| PEO Name | Dr. Blanchard | Dr. Blanchard | |||
| Measure [Axis]: 1 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Revenues | ||||
| Non-GAAP Measure Description [Text Block] | Net Income and Revenue are as reported in the company’s Annual Report on Form 10-K for each fiscal year referenced. | ||||
| Measure [Axis]: 2 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Gross Margin | ||||
| Measure [Axis]: 3 | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Measure Name | Adjusted EBITDA | ||||
| Dr. Blanchard [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| PEO Total Compensation Amount | $ 10,029,434 | $ 5,940,722 | $ 4,202,608 | $ 10,029,434 | |
| PEO Actually Paid Compensation Amount | $ 10,513,388 | 3,599,763 | 1,818,313 | 10,513,388 | |
| PEO Name | Dr. Blanchard | ||||
| Mr. Darling [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| PEO Total Compensation Amount | $ 288,753 | 288,753 | |||
| PEO Actually Paid Compensation Amount | $ (7,088,313) | (7,088,313) | |||
| PEO Name | Mr. Darling | ||||
| PEO [Member] | Dr. Blanchard [Member] | Grant Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (4,630,341) | (2,942,637) | (8,994,889) | ||
| PEO [Member] | Dr. Blanchard [Member] | Year End Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 5,294,178 | 3,254,974 | 9,337,528 | ||
| PEO [Member] | Dr. Blanchard [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (1,016,462) | (2,470,476) | 0 | ||
| PEO [Member] | Dr. Blanchard [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Year that Vested in the Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (1,988,334) | (226,155) | 0 | ||
| PEO [Member] | Dr. Blanchard [Member] | Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | 141,315 | ||
| PEO [Member] | Dr. Blanchard [Member] | Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | 0 | ||
| PEO [Member] | Dr. Blanchard [Member] | Adjustments Related to Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (2,340,959) | (2,384,295) | 483,954 | ||
| PEO [Member] | Mr. Darling [Member] | Grant Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | ||||
| PEO [Member] | Mr. Darling [Member] | Year End Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | ||||
| PEO [Member] | Mr. Darling [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | ||||
| PEO [Member] | Mr. Darling [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Year that Vested in the Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (18,351) | ||||
| PEO [Member] | Mr. Darling [Member] | Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | ||||
| PEO [Member] | Mr. Darling [Member] | Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (7,358,716) | ||||
| PEO [Member] | Mr. Darling [Member] | Adjustments Related to Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (7,377,066) | ||||
| Non-PEO NEO [Member] | Grant Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (1,051,440) | (658,333) | (962,952) | ||
| Non-PEO NEO [Member] | Year End Fair Value of Equity Awards Made During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 1,205,238 | 728,209 | 668,806 | ||
| Non-PEO NEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (274,828) | (189,171) | (64,142) | ||
| Non-PEO NEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Year that Vested in the Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | (211,562) | (63,754) | (83,186) | ||
| Non-PEO NEO [Member] | Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | 0 | ||
| Non-PEO NEO [Member] | Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | 0 | 0 | (197,641) | ||
| Non-PEO NEO [Member] | Adjustments Related to Equity Awards [Member] | |||||
| Pay vs Performance Disclosure [Table] | |||||
| Adjustment to Compensation Amount | $ (332,592) | $ (183,048) | $ (639,115) | ||
